Business
NanoViricides Announces Closing of ~$2 Million Registered Direct Offering
SHELTON, CT / ACCESS Newswire / May 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine ...
About this update from Nanoviricides, Inc.
[{"type":"text","content":"SHELTON, CT / ACCESS Newswire / May 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses and their variants cannot escape, today announced the closing of its previously announced registered direct offering (the "Offering") of 1,333,334 million shares of common stock (or pre-funded warrants in lieu thereof), together with accompanying warrants to purchase 1,333,334 common shares (the "Offering"). The Offering was made to a single, fundamental institutional investor and priced at-the-market price of US$1.50 for each common share and accompanying whole warrant to purchase one common share. Each whole warrant has an exercise price of US$1.75 per share and will be exercisable six months from issuance and will expire in three years. The Company received aggregate gross proceeds of $2,000,001 from the Offering, before deducting placement agent fees and other related expenses.","length":1104,"tagName":"p"},{"type":"text","content":"D. Boral Capital LLC acted as the exclusive placement agent for the Offering.","length":77,"tagName":"p"},{"type":"text","content":"The ordinary shares (or pre-funded warrants in lieu thereof) were offered by the Company pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333- 271706), which was declared effective by the U.S. Securities and Exchange Commission (the "SEC") on May 22, 2023.","length":301,"tagName":"p"},{"type":"text","content":"A prospectus supplement describing the terms of the proposed registered direct offering was filed with the SEC and is available on the SEC's website at https://www.sec.gov/. A copy of the prospectus supplement and accompanying base prospectus relating to the offering may be obtained, when available, from D. Boral Capital LLC, 590 Madison Avenue, 39th Floor, New York, NY 10022, or by telephone at (212) 404-7002, or by email at [email protected].","length":470,"tagName":"p"},{"type":"text","content":"This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solic...